Program
zoracopan
Its studies are led by AstraZeneca.
Furthest: phase 1, since Apr 26, 20223 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 30 open or running | phase 1since Apr 26, 2022 | Apr 26, 2022 | none ahead |
- Named in AstraZeneca’s own pipeline as
ALXN2080
, phase 1, as of Oct 30, 2026 (source).
Also a collaborator on its studies: celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2022First study: phase 1 study in HealthyFirst studyNCT05428696 · 90 enrolled · United Kingdom
- Nov 29, 2023Phase 1 study in HealthyNCT06160414 · 20 enrolled · United Kingdom
- Dec 5, 2023Phase 1 study in HealthyNCT06173596 · 60 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06173596Healthy · United Kingdom | 1 | Completed | Apr 30, 2024 | 60 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | Feb 5, 2024 | 20 |
| NCT05428696Healthy · United Kingdom | 1 | Completed | Apr 24, 2023 | 90 |
How it is read
Names in the registry
- “ALXN2080”, 3 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.